Charles River Laboratories International Inc. (NYSE:CRL) traded at a new 52-week high today of $343.47. Approximately 161,000 shares have changed hands today, as compared to an average 30-day volume of 319,000 shares.
Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company’s revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.
Charles River Laboratories International Inc. share prices have moved between a 52-week high of $343.47 and a 52-week low of $136.00 and are now trading 149% above that low price at $339.08 per share.
Charles River Laboratories International Inc. (NYSE:CRL) defies analysts with a current price ($339.08) 1.5% above its average consensus price target of $334.08.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer